Form 4: Elanco Executive Adjusts Stock Holdings

Ellen de Brabander, Executive Vice President at Elanco Animal Health, reported transactions involving company common stock.

Summary

• Ellen de Brabander, Executive Vice President of Research, Development and Regulatory Affairs at Elanco Animal Health Inc., has reported changes in her beneficial ownership of the company's common stock.
• On April 1, 2026, 40,985 shares of common stock were acquired at no cost, increasing her direct beneficial ownership.
• Additionally, on the same date, 20,288 shares were disposed of at a price of $23.12 per share.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents routine insider transactions rather than significant strategic shifts or performance indicators.

Positives

• Acquisition of 40,985 shares of common stock at no cost, indicating potential equity-based compensation or award.

Negatives

• Disposal of 20,288 shares of common stock at $23.12 per share, which could suggest a reduction in direct holdings by a key executive.

Future Outlook

No specific forward-looking statements or guidance were provided in this filing.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for executives and directors, providing transparency into insider stock transactions. Such filings are common across the animal health industry as companies utilize equity-based compensation and executives manage their personal portfolios.

Stakeholder Impact

• Shareholders: The disposal of shares by an executive may be interpreted in various ways, but without further context, it is a standard transaction. The acquisition of shares at no cost could indicate compensation or award, which is a normal part of executive remuneration.

Key Dates

Keywords

Elanco Animal Health, Form 4, SEC Filing, Stock Transaction, Beneficial Ownership, Executive Compensation, Insider Trading